Literature DB >> 17194486

Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan.

Hiroyuki Gatanaga1, Shiro Ibe, Masakazu Matsuda, Shigeru Yoshida, Tsukasa Asagi, Makiko Kondo, Kenji Sadamasu, Hiroki Tsukada, Aki Masakane, Haruyo Mori, Noboru Takata, Rumi Minami, Masao Tateyama, Takao Koike, Toshihiro Itoh, Mitsunobu Imai, Mami Nagashima, Fumitake Gejyo, Mikio Ueda, Motohiro Hamaguchi, Yoko Kojima, Takuma Shirasaka, Akiro Kimura, Masahiro Yamamoto, Jiro Fujita, Shinichi Oka, Wataru Sugiura.   

Abstract

The increasing prevalence of drug-resistant HIV transmission has become a critical epidemic in the world today. Studies in developed countries reported 8-27% of newly diagnosed HIV/AIDS patients are infected by drug-resistant strains. To determine the prevalence of drug-resistant HIV-1 among newly diagnosed cases in Japan, eight HIV/AIDS clinical centers, three public health laboratories and the National Institute of Infectious Diseases conducted a nationwide survey. Between January 2003 and December 2004, 575 newly diagnosed HIV/AIDS patients with both acute and chronic infections were enrolled in the study. Twenty-three cases, including three recently infected patients, were infected with HIV-1 having major drug-resistance mutations, including M41L, D67N, L100I, K103N, V106A, M184I, M184V, L210W, and revertant mutations at the 215 codon in reverse transcriptase and M46I in protease encoding regions. In this newly diagnosed population, we also clarified the prevalence of hepatitis virus coinfection, which was 8.8% for HBV and 4.3% for HCV. In conclusion, the drug-resistant transmission rate was 4.0% in Japan. Although this rate is significantly lower than that of other developed countries, this rate almost reaches the threshold at which baseline genotypic resistance testing would be cost-effective for all infected persons before initiating therapy.

Entities:  

Mesh:

Year:  2006        PMID: 17194486     DOI: 10.1016/j.antiviral.2006.11.012

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  17 in total

1.  Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.

Authors:  Atsuko Hachiya; Kazuki Shimane; Stefan G Sarafianos; Eiichi N Kodama; Yasuko Sakagami; Fujie Negishi; Hirokazu Koizumi; Hiroyuki Gatanaga; Masao Matsuoka; Masafumi Takiguchi; Shinichi Oka
Journal:  Antiviral Res       Date:  2009-02-21       Impact factor: 5.970

2.  Clustered epitopes within a new poly-epitopic HIV-1 DNA vaccine shows immunogenicity in BALB/c mice.

Authors:  Nazli Jafarpour; Arash Memarnejadian; Mohammad Reza Aghasadeghi; Fatemeh Kohram; Haniyeh Aghababa; Nima Khoramabadi; Mehdi Mahdavi
Journal:  Mol Biol Rep       Date:  2014-05-20       Impact factor: 2.316

Review 3.  Viral hepatitis and human immunodeficiency virus co-infections in Asia.

Authors:  Takako Utsumi; Maria I Lusida
Journal:  World J Virol       Date:  2015-05-12

4.  Japanese external quality assessment program to standardize HIV-1 drug-resistance testing (JEQS2010 program) using in vitro transcribed RNA as reference material.

Authors:  Shigeru Yoshida; Junko Hattori; Masakazu Matsuda; Kiyomi Okada; Yukumasa Kazuyama; Osamu Hashimoto; Shiro Ibe; Shin-ichi Fujisawa; Hitoshi Chiba; Masashi Tatsumi; Shingo Kato; Wataru Sugiura
Journal:  AIDS Res Hum Retroviruses       Date:  2014-12-03       Impact factor: 2.205

5.  Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan.

Authors:  Seiichiro Fujisaki; Yoshiyuki Yokomaku; Teiichiro Shiino; Tomohiko Koibuchi; Junko Hattori; Shiro Ibe; Yasumasa Iwatani; Aikichi Iwamoto; Takuma Shirasaka; Motohiro Hamaguchi; Wataru Sugiura
Journal:  J Clin Microbiol       Date:  2011-01-19       Impact factor: 5.948

6.  Transmitted drug resistance in nonsubtype B HIV-1 infection.

Authors:  Philip A Chan; Rami Kantor
Journal:  HIV Ther       Date:  2009-09-01

7.  Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia.

Authors:  Alexander Hoare; Stephen J Kerr; Kiat Ruxrungtham; Jintanat Ananworanich; Matthew G Law; David A Cooper; Praphan Phanuphak; David P Wilson
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

8.  Phylodynamic analysis of a viral infection network.

Authors:  Teiichiro Shiino
Journal:  Front Microbiol       Date:  2012-07-31       Impact factor: 5.640

9.  Prevalence of antiretroviral drug resistance mutations and HIV-I subtypes among newly-diagnosed drug-naïve persons visiting a voluntary testing and counselling centre in northeastern South Africa.

Authors:  Julius M Nwobegahay; Pascal O Bessong; Tracy M Masebe; Lufuno G Mavhandu; Benson C Iweriebor; Gloria Selabe
Journal:  J Health Popul Nutr       Date:  2011-08       Impact factor: 2.000

10.  Prevalence and epidemiological traits of HIV infections in populations with high-risk behaviours as revealed by genetic analysis of HBV.

Authors:  Y Kojima; T Kawahata; H Mori; K Furubayashi; Y Taniguchi; A Iwasa; K Taniguchi; H Kimura; J Komano
Journal:  Epidemiol Infect       Date:  2013-01-25       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.